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Abstract
Background: Although several studies have been performed on risk factors and natural course of
NASH, it seems that NASH tends to be more than a disease confined to strict boundaries. The
objective of this study was to assess the clinical and paraclinical features and risk factors for non-
alcoholic steatohepatitis (NASH) patients in an Iranian population
Methods:  Patients with histologically confirmed NASH who had elevated liver
aminotransaminases, negative serologic markers of viral or autoimmune hepatitis and no findings in
favor of metabolic liver disease were enrolled. A careful history was taken regarding alcohol intake.
Results: 53 patients consisting of 32 male and 21 female entered the study. The mean age was 37.8
± 11.3 years. Twenty-six patients (55.3%) were overweight, 15 (31.9%) obese, 40 (75.5%)
dyslipidemic, and three patients (5.7%) were diabetic. Liver biopsy showed mild steatosis in 35.7%,
moderate steatosis in 53.6%, and severe forms in 10.7%. In 80.2% of patients, portal inflammation
was present, and 9.4% had cirrhosis. The amount of increase in liver enzymes bore no relationship
with fibrosis, portal inflammation, and degree of steatosis.
Conclusions:  The patients in our study showed a male predominancy and were somewhat
younger than other studies.
Background
Non-alcoholic steatohepatitis (NASH) is a disease of
unknown origin characterized histologically by changes
similar to what is seen in alcoholic-like liver injury but in
the absence of significant alcohol intake [1,2]. NASH is
considered a type of chronic hepatitis and is a severe form
of a spectrum called non-alcoholic fatty liver disease
(NAFLD) [3]. NAFLD has four histological stages: (1) fatty
infiltration of the liver (2) fatty infiltration plus inflam-
mation (3) fatty infiltration with ballooning degeneration
(4) fatty infiltration with lesions similar to alcoholic hep-
atitis and sinusoidal fibrosis, polymorphonuclear infiltra-
tion with or without Mallory hyaline. NASH is the name
given to the third and fourth stages [4,5].
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The prevalence and clinical significance of NASH appears
to be more than what is generally believed [6–11]. Among
patients who have had liver biopsies, NASH is seen in
approximately 7 to 9 percent in Western countries
[12,13]. Ultrasonographic studies on normal population
show a prevalence of 25 percent for NAFLD in the United
States [5,14]. The disease predominantly occurs between
the ages of 40 and 60, [9,11,15] although there have been
reports in children over the age of 10 [16,17] NASH is fre-
quently associated with disorders such as insulin resist-
ance, obesity, type 2 diabetes mellitus, hyperlipidemia,
protein-calorie malnutrition, and jejeunoileal bypass sur-
gery [5,9,12,18–21] It is important to consider that NASH
can progress to cirrhosis and hepatic failure [7,8], further
underscoring its importance as a potentially serious and
life-threatening disease.
Regarding this fact that in Iran alcohol consumption is
much less than western countries, we doubted whether
the demography and risk factors of NASH in Iranian pop-
ulations is the same as what has been seen in previous
studies.
Methods
Patient selection
The cohort of patients reviewed here were selected from
all patients between 15 and 65, referred to Gastroenterol-
ogy and Hepatology Clinic of Imam Khomeini Hospital,
Tehran, Iran, from March 20, 1999 to November 21,
2001. Inclusion criteria were: 1. elevated liver ami-
notransaminases 2. histologic confirmation of nonalco-
holic steatohepatitis 3. negative serologic markers of viral
or autoimmune hepatitis (including HBsAg, HCV anti-
body (ELISA), HIV antibody (ELISA), antinuclear anti-
bodies, anti-smooth muscle antibodies, and anti-liver/
kidney microsomes type 1 antibodies) 4. no findings in
favor of metabolic liver diseases, including Wilson's dis-
ease and hemochromatosis) and negative alpha-1 antit-
rypsin. A careful history was taken with special attention
to alcohol intake and ultrasonography was performed in
all enrolled patients. Alcohol intake was asked from the
patient and at least one of the patients' companions. In
case of positive alcohol consumption, the questionnaire
used for this purpose had more detail to help the inter-
viewer to estimate the approximate amount of alcohol
consumption. Exclusion criteria were: 1. recent gastroin-
testinal surgery 2. pregnancy 3. usage of drugs known to
result in steatosis, including glucocoticoids, synthetic
esterogens, aspirin, tamoxifen, amiodarone, Calcium-
channel blockers, and methotrexate.
Of 213 patients (108 male and 105 female) who have pri-
marily been studied for elevation of serum aminotrans-
ferases in the beginning, 72 patients who had inclusion
criteria, except pathologic confirmation, consented to
undergo liver biopsy. The pathologic diagnosis of NASH
was confirmed in 53 patients and these patients were ana-
lyzed. Also we used the demographic data of the other 21
patients to avoid any selection bias in this characteristics,
which sounded to be different in our study, comparing
with previous studies.
Laboratory and pathological studies
Levels of aminotransferases, alkaline phosphatase, total
bilirubin, serum cholesterol and triglycerides, fasting
blood sugar, and prothrombin time were measured using
standard techniques. The definite diagnosis of NASH was
based on a histology showing moderate to gross macrove-
sicular fatty change with inflammation (lobular or por-
tal), with or without Mallory bodies, fibrosis, or cirrhosis.
The grading and staging of all biopsy specimens were
determined based on the method proposed by Brunt et al.
[2] All patients who had mild steatosis in their biopsy
were re-checked for HCV infection using radioimmuno-
absorbant assay (RIBA), which was negative in all.
Because of financial limitation we did not recheck those
with higher degrees of steatosis, since the diagnosis of
NASH was more probable in them. A single radiologist
performed all ultrasonographic studies and all pathologic
studies were performed and reported by one pathologist.
Overweight was defined as a BMI between 25 and 29.9 kg/
m2, and obesity as BMI equal or above 30 kg/m2. Ideal
weight for height was calculated by Hamwi Method [22]
(Men: 48.18 kg for 150 cm +/- 1.1 kg per cm over/under
150 cm; Women: 45.45 kg for 150 cm +/- 0.91 kg per cm
over/under 150 cm). Diabetes mellitus was defined as
either 1)fasting blood glucose concentration of 126 mg/
dL or higher in two occasions, or 2)a random value of 200
mg/dL or higher, confirmed on another occasion, or 3)
having a confirmed history of diabetes mellitus for which
the patient is currently receiving antiglycemic drugs. Dys-
lipidemia and insulin resistance was defined according to
guidelines of ATPIII.[23]> Thus, patients with one of the
criteria of LDL-C ≥ 160 mg/dL, total cholesterol ≥ 200 mg/
dL, triglycerides ≥ 150 mg/dL, or HDL-C<40 mg/dL were
considered dyslipidemic. Insulin resistance was defined
with presence of three of the following:
1. Abdominal obesity, defined as a waist circumference in
men >102 cm (40 in) and in women >88 cm (35 in)
2. Triglycerides ≥150 mg/dL
3. HDL cholesterol <40 mg/dL in men and <50 mg/dL in
women
4. Blood pressure ≥ 130/ ≥85 mmHg
5. Fasting glucose ≥110 mg/dLBMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/27
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Risk factors for NASH, according to previous studies,
included diabetes mellitus, hyperlipidemia, obesity, his-
tory of significant weight loss or weight gain, history of
consumption of esterogens or androgens, and extensive
abdominal surgery.
Statistical analysis
The results of quantitative variables are presented as mean
± SD and those of qualitative variables as numbers and
percentages. T test was used to compare quantitative vari-
ables between subgroups of patients, and differences
between categorical variables were analyzed by Chi
Square. Logistic regression analysis was used to assess the
effect of different factors on histological findings in liver
biopsy specimens. A significance level of 0.05 was used.
Results
Of the 53 patients whose diagnosis was confirmed by
biopsy, 32 (60.4%) were male and 21 (39.6%) were
female with the mean age of 37.8 ± 11.3 years. Mean
weight of the patients was 83.8 ± 19 kg and mean BMI was
29.3 ± 4.7 kg/m2. Twenty-six patients (55.3%) were over-
weight and 15 (31.9%) were obese (Table 1). None of the
patients had weights lower than the "ideal weight for
height". On the average, the patients had weights 36.3 ±
20.5% (ranging from 0 to 125.2%) higher than the ideal
weight and 94.3% of the patients had weights more than
10% higher than the ideal weight for their height (the
mean ideal weight for height of the patients was 61.4 ± 9.6
kg). Six patients (11.3%) had a history of considerable
weight loss and 12 patients (22.7%) reported an increase
in weight during the last year.
Three patients (5.7%) had overt diabetes mellitus. Forty
patients (75.5%) had some form of dyslipidemia; in
66.0% serum cholesterol was high, in 60.4% hypertriglyc-
eridemia was present, and both cholesterol and triglycer-
ides were high in 50.9%. Insulin resistance was observed
in 29 patients (54.7%). Seven patients (13.2%) had none
of the risk factors usually associated with NASH. The
mean ALT and AST levels were 80.9 ± 32.0 IU/L and 69.8
± 28.9 IU/L, respectively. Mean AST to ALT ratio was 0.9 ±
0.4. This ratio was below 1 in 65.3% of patients and below
2 in 96.2%.
In 31 patients (58.5%) abnormal ultrasound findings
were observed; 17% of all patients had increased liver size,
and 50.9% had hyperechogenicity, indicating fatty liver.
79.2% of patients had no or very unspecific clinical man-
ifestations, like fatigue, malaise and weakness. Different
clinical manifestations are shown in Figure 1.
Liver biopsy showed that steatosis was mild in 35.7%,
moderate in 53.6%, and severe in 10.7%. 22 patients
(41.5%) had mild, 26 patients (49.1%) moderate and 5
patients (9.4%) had severe necroinflammatory grades. In
histological staging of fibrosis, 11.3%, 18.9%, 22.6%, and
37.7% of patients had 0 through 3 scores, respectively and
in 9.4% (5 patients), liver biopsy demonstrated cirrhosis
(stage 4). The results of logistic regression analysis showed
no relationship between the level of liver enzymes and
fibrosis, necroinflammatory grading, and steatosis. Pres-
ence of insulin resistance did not have any significant
relationship with the staging and grading of the disease, as
well.
Table 1: Anthropometric and biochemical characteristics of 53 patients with NASH
Male Female Total
Number 32 21 53
Age (y) 36.0 ± 10.6 40.5 ± 11.9 37.8 ± 11.3
Weight (kg) 93.6 ± 16.5* 69.3 ± 12.0 83.8 ± 19
BMI (kg/m2) 30.7 ± 4.9† 27.3 ± 3.5 29.3 ± 4.7
Normal BMI, n (%) 7 (21.9%) 5 (23.8%) 12 (22.6%)
Obesity, n (%) 13 (46.4)* 2 (10.5) 15 (31.9)
Overweight, n (%) 12 (42.9)* 14 (73.7) 26 (55.3)
Total cholesterol (mg/dL) 229.6 ± 73.5 223.5 ± 62.5 227.0 ± 68.5
LDL-C (mg/dL) 139.5 ± 42.3 123.0 ± 43.3 134.8 ± 42.2
HDL-C (mg/dL) 47.6 ± 16.1 43.1 ± 13.6 46.3 ± 15.2
Triglycerides (mg/dL) 207 ± 83.6 184 ± 89.1 197.3 ± 85.8
FBS (mg/dL) 102.1 ± 11.4 112.8 ± 42.5 106.5 ± 28.1
ALT (IU/L) 80.3 ± 27.5 82.0 ± 38.8 80.9 ± 32.0
AST (IU/L) 68.8 ± 22.4 71.3 ± 37.5 69.8 ± 28.9
AST/ALT 0.9 ± 0.3 0.9 ± 0.5 0.9 ± 0.4
*p < 0.001, † p < 0.05 compared to female patients. ALT: Alanine Aminotransferase, AST: Aspartate Aminotransferase, BMI: Body Mass Index, FBS: 
Fasting Blood Sugar, HDL-C: High Density Lipoprotein Cholestrol, LDL-C: Low Density Lipoprotein Cholestrol.BMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/27
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In an analysis of demographic characteristics of 53 histo-
logically-confirmed NASH cases and 21 patients with clin-
ical diagnosis of NASH whose diagnosis was not
confirmed in biopsy, 56.8% of patients (42/74) were
male and 43.2% (32/74) were female. Mean age was 39.2
± 12.1 years and mean BMI was 29.1 ± 4.1 kg/m2. There
was no significant difference in these characteristics
between those who had positive biopsy and those who
had negative.
Discussion
Nonalcoholic fatty liver disease (NAFLD) seems to have
become an important medical entity and this importance
is mainly resulted from its potential to progress to cirrho-
sis and liver failure and its common occurrence in general
population [6]. Because of the low rate of alcohol con-
sumption in Iran, the prevalence might be even higher
than other countries. Regardless of the religious beliefs,
the habit of alcohol consumption in Iranian population,
in most instances, is not so heavy and frequent as what is
seen in most of the western countries.
Our patients were somewhat younger than those in previ-
ous studies (40–60 years old) [9,12,15]. Also most of our
patients were male (60.4%), while most of the previous
series showed a female predominance [10–12,19] and
only a few had more male patients than females [9]. One
of the reasons for these differences might be the failure to
rigorously rule out hepatitis C in some of the studies. We
rechecked all patients with mild steatosis for hepatitis C
infection. In the report mentioned before as showing a
male preponderance [9], also hepatitis C was excluded
with precision, and the patients had demographic charac-
teristics different from those usually reported. The male
predominancy in our study, prompted us to evaluate
whether this difference is related to the disease, itself, or is
a selection bias in patients who are referred to our clinic.
We compared these patients with other patients who pri-
marily had elevation of serum aminotransferases but did
not meet the inclusion criteria of the study. From total
number of 127 patients with aminotransferases elevation
who were excluded from the study, 52.8% were male.
Although not exclusively rejecting the selection bias, these
findings are against the assumption of a selection bias,
since there is not a significant male predominance in
other patients of our clinic. But more investigations are
mandatory in this regard. Another probable justification
of the different sex composition of our patients might be
attributed to the lower rate of alcohol consumption in our
society. Since men usually consume more amount of alco-
hol and are more at risk of alcoholic liver disease, in soci-
eties with higher prevalence of alcohol consumption,
more men are excluded from the diagnosis of nonalco-
holic steatohepatitis because of their alcohol
consumption.
The mean weight of the patients was higher than normal
as in previous reports. [11,12,18] Most patients had
abnormally high BMI's and 94.2% had weights more than
10% above their ideal body weights. 11.3% of the patients
had a history of weight loss in the year before diagnosis,
which is similar to other results [24,25].
Another difference between our results and other reports
is the relatively low prevalence of diabetes. Although
some reports have shown a prevalence of 2–5% for diabe-
tes mellitus in this group [19,26], in most of them this
prevalence is as high as 21–55% [12,9–11,18–21]. An
interesting finding is that 13.2% of our patients had none
of the known risk factors for development of NASH, and
NASH should be considered as an entity not being con-
fined to obese and diabetic patients.
Liver enzyme levels in our patients were similar to previ-
ous reports [9]. The mean AST to ALT ratio was less than 1
as expected, and in 96.2% this ratio was below 2. In alco-
holic liver disease, this ratio is usually above two, averag-
ing from 2.6 to 2.85 [24,27,28].
We observed dyslipidemia in 75.5% of our patients. Oth-
ers have reported similar prevalences (20–80%) [9–
12,20,21]. The ultrasonographic findings, such as fatty
infiltration, are usually nonspecific [29].
Relative Frequency (Percent) of Different Clinical Manifesta- tions in Patients with NASH, Tehran, 2002 Figure 1
Relative Frequency (Percent) of Different Clinical Manifesta-
tions in Patients with NASH, Tehran, 2002
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It is not usually advisable to make a diagnosis of NASH
before liver biopsy. The possibility of making an errone-
ous diagnosis is higher in NASH as compared to alcoholic
liver disease. In our study, from 74 patients selected on
clinical basis, 53 ones had NASH on liver biopsy. This fig-
ure is larger than the ones mentioned in other studies
[30–33], which is probably due to precise patient selec-
tion in the present study, exclusion of cases with low ami-
notransaminase levels, or positive markers for viral
hepatitis.
Factors affecting the pathogenesis of NASH are steatosis,
inflammation, and fibrosis [2,34–38]. The severity of stea-
tosis was similar to other reports. Also, the majority of
patients had portal inflammation. The findings on liver
biopsy were not correlated to liver enzymes, thus the
increase in liver enzymes does not seem a good estimate
of the severity of liver disease.
NASH can cause fibrosis and progress to cirrhosis. It has
been shown that this progress is seen in 8–26% of patients
[6,8,9,19]. Hepatic fibrosis, Mallory hyaline, or balloon-
ing degeneration are findings that indicate higher likeli-
hood of progression to cirrhosis [39]. Altogether, these
findings further underscore the importance of NASH and
the need to diagnose it before it causes irreversible liver
damage.
Conclusion
The epidemiology and risk factors of nonalcoholic steato-
hepatitis might be different in societies with lower rate of
alcohol consumption, although this is just a preliminary
hypothesis that should be evaluated in further studies.
Regarding the considerable prevalence of the disease, con-
finement of the diagnosis to some specific epidemiologic
and demographic subgroups does not seem so reasona-
ble, particularly in regions where the distribution of the
disease is not well-known.
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